Skip to main content

Main menu

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Editorial Policies
    • Subscribers
    • Advertisers
    • Editorial Board
    • Special Issues 2025
  • Journal Metrics
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics

User menu

  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Anticancer Research
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics
  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Anticancer Research

Advanced Search

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Editorial Policies
    • Subscribers
    • Advertisers
    • Editorial Board
    • Special Issues 2025
  • Journal Metrics
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Visit us on Facebook
  • Follow us on Linkedin
Research ArticleExperimental Studies

IFN-Á Responses in Peptide-treated Melanoma Patients Measured by an ELISPOT Assay Using Allogeneic Dendritic Cells

SUSANNE GABRIELSSON, VINCENT BRICHARD, OLIVIER DHELLIN, THIERRY DORVAL and CHRISTIAN BONNEROT
Anticancer Research January 2004, 24 (1) 171-178;
SUSANNE GABRIELSSON
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
VINCENT BRICHARD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
OLIVIER DHELLIN
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
THIERRY DORVAL
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
CHRISTIAN BONNEROT
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Info & Metrics
  • PDF
Loading

Abstract

Background: Several melanoma-specific peptides are currently used in clinical trials. However, the monitoring of the T cell response remains non-standardised and is often limited by shortage of cells. Materials and Methods: We established an IFN-Á ELISPOT assay to detect the CD8+ T cell response in HLA-A2-positive melanoma patients using pre-frozen, peptide-loaded HLA-A2-positive but otherwise allogeneic, monocyte-derived dendritic cells (DC) as antigen-presenting cells. We tested HLA-A2-positive stage III or IV melanoma patients before and after peptide immunotherapy. Results: The number of EBV and influenza-specific IFN-γ-spots were comparable irrespective of the use of autologous or allogeneic HLA-A2 immature DCs when using purified CD8+ cells as responder cells, but a high allogeneic background was seen when using PBMC. We observed modifications of the in vitro response to the melanoma peptides in three out of four responding patients, while virus responses remained constant; however, similar results were seen in the group with progressive disease. Conclusion: This demonstrates the possibility of monitoring an immune response by using allogeneic DCs, reducing the consumption of patient cells. The in vitro IFN-Á responses increased in response to the peptide therapy, however this could not be correlated to clinical outcome.

  • Received July 14, 2003.
  • Accepted October 22, 2003.
  • Copyright© 2004 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved
PreviousNext
Back to top

In this issue

Anticancer Research: 24 (1)
Anticancer Research
Vol. 24, Issue 1
January-February 2004
  • Table of Contents
  • Table of Contents (PDF)
  • Index by author
  • Ed Board (PDF)
  • Front Matter (PDF)
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Anticancer Research.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
IFN-Á Responses in Peptide-treated Melanoma Patients Measured by an ELISPOT Assay Using Allogeneic Dendritic Cells
(Your Name) has sent you a message from Anticancer Research
(Your Name) thought you would like to see the Anticancer Research web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
1 + 1 =
Solve this simple math problem and enter the result. E.g. for 1+3, enter 4.
Citation Tools
IFN-Á Responses in Peptide-treated Melanoma Patients Measured by an ELISPOT Assay Using Allogeneic Dendritic Cells
SUSANNE GABRIELSSON, VINCENT BRICHARD, OLIVIER DHELLIN, THIERRY DORVAL, CHRISTIAN BONNEROT
Anticancer Research Jan 2004, 24 (1) 171-178;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Reprints and Permissions
Share
IFN-Á Responses in Peptide-treated Melanoma Patients Measured by an ELISPOT Assay Using Allogeneic Dendritic Cells
SUSANNE GABRIELSSON, VINCENT BRICHARD, OLIVIER DHELLIN, THIERRY DORVAL, CHRISTIAN BONNEROT
Anticancer Research Jan 2004, 24 (1) 171-178;
Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
  • Info & Metrics
  • PDF

Related Articles

  • No related articles found.
  • Google Scholar

Cited By...

  • Predicting Tumor Outcome following Cancer Vaccination by Monitoring Quantitative and Qualitative CD8+ T Cell Parameters
  • Google Scholar

More in this TOC Section

  • Tissue Prognostic Markers for Clear Cell Renal Cell Carcinoma Tumor-stroma Interaction: Impact on TNM Staging Parameters
  • CA9-Positive Keloid Fibroblasts: Modulator of Local Inflammation Induced by the Hypoxic and Glycolysis-enhanced Microenvironment
  • Predictive Factors for Multiple Metastases of Clear-cell Renal Cell Carcinoma
Show more Experimental Studies

Similar Articles

Anticancer Research

© 2025 Anticancer Research

Powered by HighWire